In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AstraZeneca buys Almirall's respiratory franchise for $875mm plus earn-outs

Executive Summary

AstraZeneca PLC paid $875mm to buy Spanish drug-maker Almirall SA’s respiratory business, which contains one marketed therapy along with others in development. Almirall could get up to $1.22bn in development, launch, and sales-related earn-outs, plus additional undefined sales-related payments.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register